Annals of Oncology 13:716-720, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
1Department of Medical Oncology, Azienda Ospedaliera di Parma; 2Medical Oncology Unit, Hospital of Urbino; 3Medical Oncology Unit, Hospital of Taormina; 4Division of Medical Oncology, Azienda Ospedaliera Ospedale S. Salvatore, Pesaro; 5Division of Medical Oncology, Hospital of Ancona; 6Medical Oncology Unit, University Campus Biomedico Roma; 7Medical Oncology Unit, Hospital of Fabriano; 8Medical Oncology Unit, Azienda Ospedaliera di Treviglio; 9Medical Oncology Unit, Casa di Cura Poliambulanza, Brescia; 10Division of Medical Oncology, University of Ancona; 11Division of Medical Oncology, Azienda Ospedale Cà Granda, Milano; 12Division of Medical Oncology, University of Messina; 13Division of Medical Oncology, Hospital of Bergamo; 14AIRES Services, Milan, Italy
Received 13 June 2001; revised 27 September 2001; accepted 18 October 2001.
Background
To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TOMOX) as first-line chemotherapy for patients with advanced colorectal cancer.
Materials and methods
Previously untreated patients with metastatic colorectal cancer received raltitrexed 3 mg/m2 plus oxaliplatin 100 mg/m2, both intravenously, on day 1 every 3 weeks. Patients were re-evaluated after every third cycle and chemotherapy was continued up to tolerance or disease progression.
Results
Fifty-eight patients from 13 Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD) centers were accrued from September 1999 to November 2000. According to the intention-to-treat analysis from 58 patients, the overall response rate was 50% [95% confidence interval (CI) 38% to 62%], with three complete responses and 26 partial responses. The median overall survival (44 patients currently alive) was >9 months and the median time to disease progression was 6.5 months (range 1–15 months). The main hematological toxicity was grade III/IV neutropenia, which occurred in 17% of patients, while anemia and thrombocytopenia were uncommon. Grade III/IV non-hematological toxicities were transient transaminitis (17% of patients); asthenia (16% of patients); neurotoxicity (10% of patients) and diarrhea (7% of patients). No toxic death was observed, one patient with grade IV asthenia after the first cycle refused chemotherapy.
Conclusions
The results of this study suggest that the TOMOX combination is an effective and well tolerated regimen for the treatment of advanced colorectal cancer. Its ease of administration and patient tolerance warrant further investigation as an alternative to fluoropyrimidine-based regimens with repeated and prolonged fluorouracil infusions.
Key words: chemotherapy, colorectal cancer, oxaliplatin, raltitrexed
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Lecomte, B. Landi, P. Beaune, P. Laurent-Puig, and M.-A. Loriot Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy. Clin. Cancer Res., May 15, 2006; 12(10): 3050 - 3056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iop, A. M. Manfredi, and S. Bonura Fatigue in cancer patients receiving chemotherapy: an analysis of published studies Ann. Onc., May 1, 2004; 15(5): 712 - 720. [Abstract] [Full Text] [PDF]
|
|